Apple’s stock could underperform, especially without an ‘all-glass’ iPhone, this analyst warns
A Jefferies analyst says that it may be harder than it looks for Apple to roll out dramatically more expensive devices in a bid to boost profitability.
A Jefferies analyst says that it may be harder than it looks for Apple to roll out dramatically more expensive devices in a bid to boost profitability.
Key insight: In addition to concerns like liquidity with private credit, there are tax complications that many clients and advisors don’t know about. Expert quote: “I think the alts mania is going to start playing out that people don’t want them anymore. The clients have no idea how these things work.” — Samuel Diarbakerly of…
The latest data on spending shows it continues to outrun income growth as higher prices absorb more of the household budget. June offered another example: The Personal Consumption Expenditures reading for that month indicated that consumers increased their spending 0.3% from May while personal income, disposable income and wages each rose 0.2%, as reported by…
Adani Group has rejected allegations that Adani Green Energy Ltd reduced the declared cost of its 1,500-MW Tarali pumped storage project to cut statutory wildlife payments. It said the lower figure in an online forest and wildlife clearance proposal reflected only preliminary site investigations and surveys, while the State Board for Wildlife considered the full…
Oil falls despite fresh attacks on Saudi energy infrastructure !“#$%&‘()*+,–./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|} !“#$%&‘()*+,–./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}
NEW YORK, Aug. 16, 2026 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Datavault AI Inc. (NASDAQ: DVLT) between September 4, 2024 and October 30, 2025, inclusive (the “Class Period”), of the important October 5, 2026 lead plaintiff deadline. So what: If you purchased Datavault AI securities…
LUND, Sweden, Aug. 18, 2026 /PRNewswire/ — Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA). “This first commercial living donor transplant patient in Australia…